At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Tanguy Seiwert, MD, from The University of Chicago Medicine, Chicago, IL, discusses the subgroup and biomarker analysis of LUX-H&N1, a phase 3 clinical trial comparing second-line afatinib, an ErbB family blocker, with methotrexate for the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
LUX-H&N1: Phase 3 trial of afatinib versus methotrexate for head and neck squamous cell carcinoma
5th February 2016
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now